There were several occasions we were hoping a buyout would happen, but it did not.
After the reduce it – No Buyout
During the trial prior to Jude Dusaster – No Buyout
After the European Approval – No Buyout
Two years after the U.S approval and 6 months after the EU approval, we are still sitting here hoping for a buyout. Perhaps nobody is interested? Pfizer has been showing interest in buying cancer drugs and they seem to be interested in during drugs that are in Phase 1, Phase 2 stages for future revenue. Vascepa would be an immediate revenue stream. However, Pfizer has been bringing in boatload of money with this covid situation. So, what I am saying is they may not have a need for a drug that brings immediate revenue but rather interested in drugs 5-10 years down the road. My concern is that are we going to be left with the “Going it alone” option? If so, it would take many more years.
Market Data 
Markets 
AI
